Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence

Executive Summary

Sponsor hopes to demonstrate that FDA's process for reviewing extended-release abuse-deterrent opioids may not be appropriate for an immediate-release product. Apadaz would be the first immediate-release opioid with an abuse-deterrent claim if approved.

Advertisement

Related Content

US FDA Review Management Challenged After Spate Of Complete Response Letters
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?
KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
FDA Latest Opioid Dilemma: Can Apadaz Stop Snorting Abuse – And Does That Even Matter?
Dispute Resolution Strategies: FDA Clarifies Which Issues Can Be Appealed
If At First You Don’t Succeed, Try Dispute Resolution
FDA Dispute Resolution Process Invoked About 10 Times Annually

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register